Exciting (NON-Covid19) news flash from the world of (digital) diagnostics from market access, policy, product launches, start-ups and industry trends perspectives.
Regulatory
1. IVDR implementation by 2022 'highly doubtful,' trade group warns
MedTech Europe published a clearly worded position paper in late July, documenting the industry concerns on the lack of timely guidance to plan for this major regulatory change. Companies are requesting a postponement of the May 2022 deadline, amongst other things.
Reimbursement
2. CVS builds out digital health program with five more companies
US-based Pharmacy Benefit Managers are increasingly recognising the value of digital solutions.
Partnerships, Company Performance and Scientific Developments
3. Abbott tops Q2 estimates aided by 233.6% jump in molecular diagnostics
Covid-19 lab tests and rapid tests boosted performance.
4. Thrive flourishes, raises $257M to carry forward its cancer-seeking blood test
CancerSEEK was able to identify tumours located in 10 different organs, with 65% discovered before the disease spread to other parts of the body.
5. Novartis, Propeller Health co-package new asthma treatment
Digital health and sensors to help monitor medication adherence and track patients’ condition. Co-package available in EU in 2020.
An advanced algorithm by Tel-Aviv-based Ibex Medical Analytics, that goes beyond detection into areas like tumour grading and sizing,
A chatbot that can answer more than 500,000 questions related to hereditary cancer, potentially making the lives of doctors and patients easier in an era of information overload.
8. A Blood Test for Alzheimer's? Markers for Tau Take Us a Step Closer
Scientists have found that the p-tau 217 blood-based biomarker identifies Alzheimer's. It is more accurate than its much-researched counterpart p-tau 181.
9. Chugai and Biofourmis to develop digital pain assessment tool for patients with endometriosis
Biosensors and AI algorithms to objectively assess pain for women with the condition.
The upgrade adds clearer insight into both the patient’s current rheumatoid arthritis inflammation and the future risk of joint damage.